In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Barr buys Duramed

Executive Summary

Specialty generics and proprietary pharmaceuticals company Barr Laboratories has agreed to buy women's health care pharmaceutical specialist Duramed Pharmaceuticals in a stock swap. Barr says it will issue approximately 8.25mm of its common shares, worth $588.5mm (based on Barr's average trading price). Duramed stockowners get one Barr share for every 3.9 Duramed common held.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Stock

Related Companies